<DOC>
	<DOCNO>NCT02557360</DOCNO>
	<brief_summary>Primary biliary cirrhosis ( PBC ) chronic cholestatic liver disorder may lead several symptom intractable pruritus chronic fatigue , significantly impair patient quality life . Recent study show , chronic liver disease associate acquire deficiency S-adenosyl-L-methionine ( SAMe ) synthetase , responsible synthesis SAMe methionine . SAMe deficiency associate impaired detoxification hepatoprotection exacerbate liver injury . Supplementation SAMe proven useful several liver disease . The study group include 20 patient PBC diagnose European Association Study Liver ( EASL ) criterion , already treat ursodeoxycholic acid ( UDCA ) . They receive SAMe dose 1600 mg bd period 6 month . Both clinical laboratory aspect analyze : liver serum biochemistry , serum urine bile acid metabolite , transient elastography health relate quality life .</brief_summary>
	<brief_title>Effectiveness S-adenosyl-L-methionine Patients With Primary Biliary Cirrhosis</brief_title>
	<detailed_description>Background : Primary biliary cirrhosis chronic cholestatic liver disorder may lead end stage liver disease cause death require liver transplantation . Additionally , significant proportion patient suffers complication relate impaired bile secretion intractable pruritus , chronic fatigue , osteoporosis lipid disturbance . They significant consequence patient well , quality life economical aspect health care system . Pathogenesis PBC remain fully elucidate . Recent study show , chronic liver disease associate acquire deficiency S-adenosyl-L-methionine synthetase , enzyme responsible synthesis SAMe methionine . SAMe initiate two important protective metabolic pathway : transmethylation transsulphuration . As result later , glutathione , taurine sulphate group synthesize . Thus SAMe deficiency associate impaired detoxification hepatoprotection exacerbate liver injury . Supplementation SAMe proven useful alcoholic liver disease , obstetric cholestasis elimination hepatitis C virus ( HCV ) . The investigator ' study experimental model cholestasis induce vitro lithocholic acid 17-beta estradiol glucuronide show supplementation SAMe exert significant anticholestatic effect . Interestingly , simultaneous administration SAMe ursodeoxycholic acid ( UDCA ) exert additive effect . Methods : The study group include 20 patient PBC diagnose EASL criterion , already treat UDCA . They receive UDCA dose 13 - 15mg/kg bw plus SAMe dose 1600 mg bd period 6 month . The key aim project analyze effect SAMe health relate quality life liver biochemistry . Blood urine sample ( 24hr urine collection ) collect liver biochemistry metabolite bile acid . Additionally transient elastography perform 6 month SAMe treatment .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<criteria>primary biliary cirrhosis diagnose EASL criterion ; treatment UDCA least 3 month . overlap syndrome ( i.e . autoimmune hepatitis ) , viral hepatitis ; decompensated liver cirrhosis ( ChildPugh class BC ) ; disease affect quality life mood : decompensated diabetes mellitus , renal insufficiency require dialysis , malignancy , heart failure â‰¥ New York Heart Association ( NYHA ) II , rheumatoid arthritis , asthma , mood disorder , depression ; treatment : steroid , statin , rifampicin , antidepressant .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>liver injury</keyword>
	<keyword>detoxification</keyword>
	<keyword>S-adenosyl-L-methionine</keyword>
	<keyword>quality life</keyword>
</DOC>